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A continuous random access immunoassay analyser, the COBAS
Core II, was evaluated in the central laboratory of the Tumor
Biology Center in Freiburg, Germany for three months. The
performance of six COBAS Core immunoassays (AFP, CA 15-
3, CEA, PSA, TSH and FT4) were investigated. Intra-assay
imprecision (CVs ranging from 1"8 to 4"9%) and inter-assay
imprecision (CVs rangingfrom 2% to 8"5%) was good. Accuracy
was verified with three commercially available quality control sera.
In particular, the automatic dilution ofthe COBAS CoreHproved
useful and gave superior reproducibility compared to manual
dilution. A method comparison with the Abbott AxSTMTM
was alsoperformed--using more than 600 routine patient samples.
Good correlation was foundfor all assays (slopes ranging from
0"92-1"28, correlation rs =0"93-0"98), except for PSA because
human spedmens were used. The COBAS Core H was evaluated
for ease ofuse and effciency compared to the Abbott AxSTM. The
performance of the COBAS Core H immunoassay analyser was
similar to the laboratory’s routine analyser; the COBAS Core H
required much less operator time. The COBAS CoreH wasfound
to be well suited to an oncology laboratory.
Introduction
Clinical laboratories are under constant pressure to
provide a high-quality service, improve efficiency and
keep costs to a minimum so they need diagnostic systems
with the highest standards of performance, convenience,
and cost effectiveness.
Roche Diagnostics recently launched the COBAS Core
II, which is a fully automated, continuous random access
immunoassay analyser, capable of running up to 150
tests]hour with a maximum of 18 on board reagents,
continuous reloading of samples and reagents and auto-
dilution of samples. The COBAS Core II was evaluated
in the central laboratory of the Institute for Clinical
Pharmacology in the Tumor Biology Center, Freiburg,
Germany fromJuly to November 1995. The objectives of
the evaluation were to check the analytical performance
with selected thyroid and tumour marker parameters, to
look at the reliability, ease of use and efficiency of the
analyser under routine conditions and in comparison to
an analyser already installed in the laboratory.
Materials and methods
COBAS Core H immunoassay analyser
The COBAS Core II immunoassay analyser (Roche
Diagnostics, Switzerland) is a random access automated
immunochemistry analyser. The test instrument’s menu
included 45 tests in a ready-to-use format, with piercable
caps comprising assays for oncology, retrovirus, hepatitis,
TORCH, thyroid, and fertility testing.
The following assays were performed in this study:
COBAS Core EIAs: thyrotropin (TSH), free thyroxine
(FT4), thyroxine (T4), triiodothyronine (T3), alpha-1-
fetoprotein (AFP),/3-human chorionic gonadotropin (/3-
hCG), cancer antigen 15-3 (CA 15-3), carbohydrate
antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125),
and prostate specific antigen (PSA), carcinoembryonic
antigen (CEA), and the improved version CEA (update).
The test principles are described in more detail in the
reagents section of this paper.
In the COBAS Core II analyser, samples are analysed in
a patient-oriented mode, and STAT tests can be added
without interrupting any tests in progress. The instru-
ment offers continuous loading of samples and reagents,
supported by LED indicators on the rank platform.
Different types of primary tubes, and a variety of
secondary tubes, can be used. The COBAS Core II offers
automatic pre- and post-dilution of samples with opera-
tor definable dilution factors of up to 1:106. Barcoded
samples, as well as sample and reagent racks, are
identified by a laser barcode scanner. Menu-structured
software in a Windows NT environment includes an on-
line help facility guiding the user through all functions
and operations. The COBAS Core II can be linked to a
computer.
Most of the COBAS Core assays have a total assay time
of less than 60 minutes. The maximum throughput is 150
samples per hour.
The specifications according to IFCC recommendations
[1] of the COBAS Core II are shown in table 1.
Reagents
The COBAS Core immunoassays are solid phase enzyme
immunoassays (EIA) using competitive binding, sand-
wich, and antibody detection; test formats are shown in
table 2(a). Essentially, a large bead, coated with defined
amounts of antigen or antibody, is incubated with serum
or plasma containing the analyte. Depending on the test
format, a washing step may be included before a horse-
radish peroxidase (HRP)-conjugate is added to detect
bound antibody or antigen. This is followed by a final
washing step. The substrate H202/3,3’,5,5’-tetramethyl-
benzidine (TMB) is added to detect the bound HRP-
conjugate and the OD is read off at 650 nm. All steps are
fully automated on the COBAS Core II immunoassay
analyser.
Full calibration or recalibration using one calibrator is
possible. In the course of this evaluation, some tests were
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Table 1. Specifications of the GOBAS Gore H immunochemistry system according to the TFCG guidelines [1].
General information
Method of analysis:
Throughput:
System operation:
Mode ofsampling:
Transport:
Samples
Nature of specimen:
Specimen pretreatment:
Specimen container:
identification system:
Specimen aspiration
and dispensing:
Chemical processor
Test menu:
Measurement:
Calibration:
Reagent dispending:
Reaction vessel:
Mixing:
Washing:
Incubator and
temperature control:
Signal measuring:
Data handling:
COBAS CORE II immunochemistry system (Roche Diagnostics, a Division ofF. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124, CH-4070 Basel).
Listing of specification as of October 1995.
Random access, sample selective analyser
Heterogeneous enzyme immunoassays utilizing big bead technology as solid phase, horse-radish peroxidase
as marker enzyme (conjugate) and 3,3’,5,5’-tetramethyl-benzidine (TMB) as substrate.
Up to 150 tests per hour, depending on the test mix.
Samples are analysed in patient-oriented mode. STAT tests can be added without interrupting other tests
already in progress. Continuous loading of both samples and reagents is possible.
X, Y, Z robotic transfer mechanism containing the sample and reagent dispenser and the bead dispenser.
Rack system: sample racks and reagent racks loaded on a rack platform with 14 slots.
A sample rack needs one slot, a reagent rack needs two slots. Up to 12 sample racks with maximum of 180
samples or up to six reagent racks with a maximum of 18 tests can be loaded at any one time. Each sample
rack can accommodate 15 sample tubes, and each reagent rack up to three tests. A red[yellow/green LED
display indicates the rack status.
Serum, plasma, urine, amniotic fluid.
No specimen pretreatment is required. Automatic pre- and post-dilution with operator definable dilution
factors in a range of 1"1-1"1,000,000.
Sample tubes with volumes of3-5ml up to 10ml. Secondary cups such as Biocups (7001xl) and Microcups
(1500 lxl, for example Eppendorf) can be positioned with an adapter.
Specimen identified by rack- and position barcode. Positive patient identification by barcode possible. The
barcode scanner supports the following symbologies: Code 128, Code 3 of 9, Codabar, 2 of 5 Interleaved
with up to 20 characters.
500tl syringe driven by linear stepper motor. Sample volume: 3-2501xl selectable in steps of lxl.
Capacitive level detection is used for level sensing of samples and reagent. Sample carry-over: less than
0"5 ppm checked with HBsAg test. The sample and reagent probes are cleaned after each work cycle.
Discrete.
Full test menu with 45 assays from the following test groups: oncology, thyroid, fertility, TORCH, hepatitis,
retroviruses.
Spectrophotometric (bichromatic) measurement. Calculation of rate values corresponds to an endpoint
measurement against blank.
Full standards with up to six calibrators (test dependent), recalibration with one or two calibrators possible.
Linear interpolation for quantitative tests.
One 500 lxl syringe for reagent, conjugate and diluent and one 1000 tl syringe for substrate, both driven by
linear stepper motor.
Conjugate/diluent volume: 3-470 Ixl selectable in steps of tl.
Reagent volume: 10-470 I1 selectable in steps of Ixl.
Substrate volume: 500 tl (fixed).
Polystyrene reaction tubes, one tube is used for each test. Tubes are supplied in prepacked cassettes holding
120 tubes. Four tube cassettes can be loaded onto the tube platform. The tubes are automatically
transferred from the tube platform to the analyser and back by an X, Y, Z robotic tube transfer mechanism.
Non-invasive mixing of sample, reagent and conjugate during incubation by intermittent shaking of the
incubator at 720-800 rpm, circular shaking mode. Mixing ofsample and sample diluent by circular shaking
of the workstation A1 [2.
Bound/free separation by washing the beads with deionized water. The number of washing steps (one or
two) is test dependent.
Thee incubator is automatically loaded and unloaded with up to 297 reaction tubes. Heating by thermistor
controlled temperature system, the temperature is maintained at 37C 4- IC (air bath). Minimum 5 min
needed to reach operating temperature after power on. The incubation time is test dependent and ranges
from 15 rain (for example ontology assays) to 2 h (retroviruses).
Spectrophotometer with halogen lamp (spectral range 400-750 nm) and two band pass filters selecting two
wavelengths: 650nm (measuring wave length) and 492nm (reference wavelength); inaccuracy of
wavelength: 4-3 nm; Band width: 10nm 4-3 nm; silicon photodiode used for detection. Linearity range:
Abs =0-2A with linearity error of < 2%. Measuring range: Abs= 0-3-5 A. Photometric reproducibility:
(1 SD) <_0"002 at 1"0 A, <_0"01 at 2"0 A.
Windows NT operating system with COBAS CORE II user interface including the following features: on-
line help facility; Profile and conditional profile testing; automatic or manual result acceptance; absorbance
values available for inspection by patient ID or test type; completely integrated system checks with self-
diagnostic messages.
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Processor:
Output:
Data storage:
Requirements
Power requirements
Powerfailure:
Water requirements:
Waste Handling
Environmental
conditions:
Physical Dimensions:
Three RS232 bidirectional ports, one unidirectional parallel port for printer LAN for various protocols
(optional)
Intel DX 486 CPU, 16 Mbyte RAM.
24-1 cm (91/2 in.) VGA colour monitor, result output via printer and/or interface.
2"5 in, 350 megabyte hard disk drive, 3-5 in, 1"44 megabyte floppy disk drive.
Line voltages: 100 to 125 V/200 to 240V.
Current: 5A (220V) or 8A (110V).
Line frequency: 50--60Hz (4-2 Hz).
Power consumption: 1000VA maximum.
Software is protected against momentary power failure for 20 ms by battery.
Laboratory reagent grade type I or double-distilled water < "5 gS conductivity. Supply via water reservoir
or via direct connection. Water consumption 5 to 71 per hour in operating mode.
Liquid waste disposal via waste reservoir or via direct connection to sanitary sewer system.
Operating temperature: 15-32C (59-89F).
Relative humidity: maximum 80% at 32C (89F).
Weight: 110 kg (242 lb.).
Width: 99cm (39 in.).
Depth: 66cm (26 in.).
Height: 76 cm (30 in.).
run with full calibration, some with recalibration. All
analytes determined with the COBAS Core II were
calibrated at the beginning of the evaluation and were
recalibrated according to the recommended time interval
of minimum 14 days.
Abbott AxSYM and Abbott IMx System
The Abbott AxSYM System (Abbott Laboratories,
USA) is an automated random access immunoassay
analyser which uses three different technologies: micro-
particle capture enzyme immunoassay (MEIA); fluores-
Table 2(a). Specifications of the COBAS EIA assays used with the COBAS COREH during the evaluation.
Type of EIA Measuring Reference Sample Incubation High dose
Analyte (quantitative) range of test range volume Sample type time hook effect
AFP One-step 0"25-275 ng/ml < 7"88 ng]nl 50 gl Serum, amniotic 30 min > 4"87.104 ng]ml
sandwich (97"5% fluid
fl-HCG One-step 1-25-200mIU/ml <4"0mIUml 50gl Serum, plasma 45min >6.106mIU/ml
sandwich (99"0%)
CA 19-9 Two-step 2-400 U/ml < 37 U/ml 50 gl Serum, plasma 75 min NA
sandwich (97"5%)
CA 15-3 Two-step 2-400 U/ml < 30 U/ml 5 gl Serum, plasma 75 min NA
sandwich (98%)
CA 125 One-step 0"45-540 U/ml < 35 U/ml 50 gl Serum, 45 rain > 2"8.105 U/ml
sandwich (97"5% heparin-plasma
CEA One-step 0"2-50 ng/ml
4 < 5 ng/ml 50 gl Serum, plasma 45 rain > 7.105 ng/ml
sandwich (97"5%) a
PSA One-step 0"2-120 ng/ml < 4"0 ng/ml 50gl Serum, plasma 30min > 2. 104 ng/ml
sandwich (99%)
TSH One-step 0-03.500 mlU/1 0"2-3-2mlU/1 100gl Serum, plasma 45 rain > 3. 000 mlU/1
sandwich
VI’4 Two-step 2-3-110 pmol/l 10-27 pmol/l 5 gl Serum, plasma 47 min NA
back titration
T3 One-step 0" 5-7"0 ng/ml 0"8-2"0 ng/ml 50 gl Serum, EDTA, 45 min NA
competitive heparin-plasma
T4 One-step 0"35-33"0 gg/dl 5"0-11-3 gg/dl 20 gl Serum, 45 min NA
competitive heparin-plasma
antigen 15-3; Ca 125 cancer antigen 125; CEA carcinoembryonic antigen; PSA prostate-specific antigen; TSH thyroid
stimulating hormone (Thyrotropin); FT4 --free thyroxine; T3 3,5,3’-triiodothyronine; T4-- 3,5,3’,5’-tetraiodthyronine (Thyroxine).
2 Percentage of healthy non-pregnant subjects.
a Percentage of healthy subjects.
4CEA (update): 0-1O0 ng/ml.
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Table 2(b). Specifications of comparative methods and instruments used in the evaluation.
Measuring range Sample Incubation
Analyte Method of test volume time
Detection Instrument
limit [Abbott]
AFP MEIA 0-350 ng/ml 150 tl 15 min 0-4 ng/ml AxSYM
CA 19-9 MEIA 0-500 IU/ml 150 tl 33 min 2"0 IU/ml AxSYM
CA 15-3 MEIA 0-250 U/ml 150 tl 45 min < 0"2 U/ml IMx
CA 125 MEIA 0-600 U/ml 150 tl 42 min 0-45 U/ml IMx
CEA MEIA 0-500 ng]ml 150 tl 30 min 0"5 ng/ml AxSYM
fl-HCG MEIA 0-1000 mIU/ml 150 tl 9 min 2"0 mIU/ml AxSYM
PSA MEIA 0-100 ng/ml 150 tl 19 min 0-1 ng/ml AxSYM
TSH MEIA 0-100 mIU[l 150 tl 18 min 0-08mIU]1 AxSYM
FT4 MEIA 0-77 pmol/l 150 tl 18 min 5-13 pmol/l AsSYM
T3 MEIA 0-80 ng]ml 150 tl 26 min 0-3 ng/ml AxSYM
T4 FPIA 0-24 tg/dl 150 tl 10 rain 1"05 tg/dl AxSYM
Including additional volume for postdilution and dead volume when Abbott sample cups were used.
Abbott Laboratories, North Chicago, Illinois, USA.
cence polarization immunoassay (FPIA) and ICIA (Ion-
capture immunoassay) [2, 3, 4].
The Abbot IMx System is an automated immunoassay
analyser system using two different technologies, MEIA
and FPIA. Specifications of the comparative methods are
shown in table 2 (b).
Precision study
Intra- and inter-assay precisions were determined using
the BioRad Lyphochek Immunoassay Control Serum
Level 1, 2 and 3 (BioRad, USA; Item No. C-37-5-IA,
Lot No. 93000). This multicontrol is an artificial lyophi-
lised control serum prepared from human serum. It was
used for all thyroid hormones and all tumour markers,
except for the tumour markers CA 15-3, CA 125 II, and
CA 19-9, where the BIOREF RM16 Multimarker Con-
trol (BIOREF GmbH, Germany; Item and Lot No.
920161) was used and for CA 15-3 the BioRad Lypho-
chek Tumour Marker Control Level and 2 (BioRad
Item No. 580, Lot No. 64200) was used. All analytes in
the precision study were checked with the lot specific
ready-to-use test kit control and with a dedicated human
serum pool, prepared, aliquoted and frozen at -20C at
the beginning of the second phase.
The precision acceptance criteria for tumour markers
were taken from Quality Control and Standardization of
Tumour Marker Test [6], and the criteria for TSH were
taken from Jay et al. [7].
Intra-assay imprecision
For the intra-assay imprecision, the corresponding qual-
ity control sera and human serum pools were analysed in
two independent runs with 20 replicates covering a time
period of at least 14 days. The following analytes were
checked: AFP, CA 15-3, CEA (update), PSA, TSH. FT4.
The lyophilized control sera were reconstituted freshly
before each run. A human serum pool for each analyte
was freshly prepared before each run. Mean, standard
deviation and coefficients of variation (CVs) were cal-
culated for each day.
Inter-assay imprecision
For the determination of between-series imprecision, the
corresponding quality control sera and human serum
pools were assayed in duplicates in up to 13 independent
runs covering a time period of at least seven days for the
following analytes: AFP, CEA, CEA (update), CA 15-3,
PSA, TSH, FT4, and T3. Mean, standard deviation, and
CVs were calculated by using all data obtained.
Daily quality-control run
To estimate the imprecision under real laboratory con-
ditions, quality control results produced in August 1995
and October 1995 were analysed. This was done on the
COBAS Core II and on the Abbott AxSYM using
BioRad Lyphochek Immunoassay Control Serum levels
1, 2, and 3. The number ofresults per month ranged from
10 to 20.
Accuracy
The values obtained from the first three runs in the inter-
assay imprecision analysis were compared with the
assigned values of the different control materials (if
available for the analyte) to estimate the accuracy of
the COBAS Core EIAs.
Dilution
To compare automatic dilution with manual dilution,
the accuracy and reproducibility of the automatic dilu-
tion feature of the COBAS Core II was estimated.
The PSA concentration in a human serum pool was
determined for three dilution ratios (1:10, 1:50, 1:100)
and in a single human sample with two dilution ratios
(1:50, 1:100). The dilutions were performed using the
automatic dilution feature ofthe COBAS Core II, and by
manual dilution. The diluted samples were assayed-in
duplicate on two consecutive days. Both samples were
diluted using the Cobas Diluent I.
In addition, the inter-assay imprecision of the CEA
assay was determined using a human serum pool, the
inter-assay imprecision of the AFP assay was determined
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using the Lyphocheck Immunoassay Control Serum
Level 3, both automatically diluted 1" 10 on the COBAS
Core II.
Method comparison
A method comparison was performed using approxi-
mately 600 routine patient samples. TSH, T3, T4,
AFP, CEA, and PSA were measured in parallel on
COBAS Core II and Abbott AxSYM; CA 125 and CA
15-3 results were compared against the Abbott IMx.
The comparison between the COBAS Core II and the
Abbott AxSYM results was performed using Passing and
Bablok’s regression analysis [8, 9, 10]. Bland and
Altmann’s graphical presentation [11] was used to assess
the degree of agreement between the two methods.
All sera were measured singly. Where there was a
discrepancy the two methods were repeated if sufficient
serum volume was available. Discrepant results were
detected on the basis of the Bland and Altman analysis
[11]. They were considered to be discrepant if they
exceeded the 95% confidence belt for the difference of
the two methods. Discrepant values which could not be
repeated due to lack of serum ,were included in the
calculation and were also listed in a separate table.
Time study
Direct operator times over a period of five days were
calculated according to the guidelines developed by a
joint working group of the Austrian, German, and Swiss
Societies of Clinical Chemistry and for Laboratory
Medicine [12].The time required to perform N tests
can be calculated by using the equation:
tp t.r + t, N
where tp is the operator time; tf is the sum of fixed
times--start-up time, preparation time for reagents,
supply of consumables, waste disposal, preparation time
for calibrators, controls and reagents, all maintenance,
and shut-down procedures; t is the sum ofvariable times
(for N analysis)--all procedures dealing with pre-
paration and handling of the samples, for example
pipetting, diluting, and placing the samples on the
instrument; N is the number of the analyses performed.
The ’fixed’ and ’variable’ times were measured with the
COBAS Core II and the Abbott AxSYM under the
following laboratory conditions--use of barcoded pri-
mary tubes; manual order entry for patient samples;
different tumour marker and endocrinology assays in-
stalled on both analysers.
Results and discussion
Imprecision
The results of the intra- and inter-assay imprecision are
summarized in table 3(a). Both the COBAS (2ore assays
and the COBAS Core II system demonstrated good
reproducibility overall.
Intra-assay imprecision
All thyroid assays were very precise, with intra-assay CVs
ranging from 1"9 to 4"8%, verifying the assay specifica-
tions given by the manufacturer of _<5"5% for TSH and
_<6"0% for FT4.
The intra-assay imprecision was between 1"8 and 4"9%
for the tumour marker assays for all sample materials
used. Only PSA gave a CV of 6"4% at a very low
concentration of 0"6 ng/ml, far from the cut-off value of
4 ng/ml. All CVs, except for the low level serum pool for
PSA, were within the limits (<5%) given in Quality
Control and Standardization of Tumour Marker Tests [6].
Inter-assay imprecision
CVs for the TSH assay ranged from 2"1% to 4"2%. No
value exceeded the acceptance limits of 10-15% set by
the American Thyroid Association [7] and the specifica-
tions of Roche Diagnostics of <_6"5%.
The imprecision for FT4 was less than 5"7% for the
low and medium conrol sera and for the human serum
pool. The CV for the high control sera was 8"5% and
therefore outside the manufacturer’s specification of
<_8%. However, the concentration level of these samples
(72"3 pmol/1) was outside the clinical decision range.
The CVs for T3 ranged from 2"1 to 7"7%, and were
therefore all within the manufacturer’s specification
(<_8%).
In addition, the imprecision for the selected thyroid panel
showed good correspondence to results found in a
recently published thyroid study [13], although a better
imprecision for T3 in the high measuring range was
obtained.
Inter-assay CVs for all tumour markers tested ranged
from 2"0 to 7"8%, therefore they met the specifications
for the inter-assay imprecision of <5-8%, suggested
in Quality Control and Standardization of Tumour Marker
Tests [6].
The imprecision for the COBAS Core CEA assay was
close to the upper limit ofthe specification claimed by the
manufacturer (_<8%). An improved version of the CO-
BAS CEA EIA, which is currently in development, was
tested and found to give a significantly better precision
with a median CV of 5"7%.
The measured values for the COBAS Core PSA assay
agreed with the data published by Schambeck et al. [14].
The inter-assay imprecision for the CA 15-3 EIA assay
(CV less than 5%) was superior to results reported in an
evaluation of three CA 25-3 assays [15].
Daily quality-control run
Results of the daily control runs are presented in figure 1.
Similar CVs between COBAS Core II and Abbott
AxSYM were observed for the following assays: T3
(except Lyphochek Level 3 where AxSYM showed better
results),/3-hCG, CEA, CA 19-9 and PSA (but there was
a larger span ofCVs for AxSYM). The COBAS Core II
showed better CVs for TSH and AFP, whereas the T4
assay on the Abbott AxSYM was more precise.
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Table 3(a). Intra-assay and inter-assay imprecision of the COBAS Core IL Mean values and coefficients of variation.
Intra-assay
Mean CV% Inter-assay
Assigned
Analyte Control material value Day Day 2 Day Day 2 Mean CV% N
AFP Lyphochek I 25-0 26"9 27"6 3" 2"7 25"4 3" 26
(ng/ml) Lyphochek II 112"0 122"4 127-5 2-8 3"0 118"2 7-2 26
Kit control 31-3 31-4 32"4 3"3 2"6 31"2 3"2 26
Human serum pool 29" 1"44 3"2 4"9 8"5 2"5 26
CA 15-3 Lyphochek I 13"7 5-0 26
(U/ml) Lypho. Tumor Ctrl. 11"0 12"5 2"5
Lypho. Tumor Ctrl. 2 32"0 32"9 3"2
BiorefRM 16 low 19"0 18"9 18"7 2"6 3-1 19"5 4"3 26
BiorefRM 16 high 67"0 63"5 63-8 2"9 3"1 66"7 4-6 26
Kit control 31-0 30"4 30"8 2"5 2"3 31-1 4"4 26
Human serum pool 77"6 3-6 26
CEA Lyphochek I 2"8 2"8 6"7 26
(ng/ml) Lyphochek II 13" 13"5 7"8 26
Lyphochek III 29"6 29"5 6"0 26
Kit control 7"5 7"5 6"5 26
Human serum pool 13"0 5"2 242
CEA Lyphochek I (2"8) 2"7 2"6 3"8 4-1 2-5 5"8 26
(update) Lyphochek II (13-1) 11-3 11-7 2"7 2"3 11"8 5-7 24
(ng/ml) Lyphochek III (29"6) 24"6 26"5 3-8 3"6 26"6 3"9 26
Human serum pool A 2"8 2"6 4-3 3"7 5-5 5"0 222
Human serum pool B 19"6 18"7 2"5 2"2 38"7 5"7 222
PSA Lyphochek I 2-6 2"6 2"7 3"3 3" 2-6 4-2 26
(ng/ml) Lyphochek II 8-6 10"0 9-9 1-8 2"8 9-9 3"2 26
Lyphochek III 79"8 95"4 92"4 2"2 3"4 91-7 2"0 26
Kit control 10"9 11 "0 11 "0 2"3 2"3 10-8 2"4 26
Human serum pool 0-6 0"6 6"4 6"1 77"5 2"9 26
TSH Lyphochek I 0"97 0"94 0-94 3-3 4"5 0-89 4"2 26
(mIU/1) Lyphochek II 6"4 6"6 6-6 2"2 2-8 6-7 2"9 26
Lyphochek III 22"5 24"2 23"3 2-4 2"0 23"7 2"2 26
Kit control 2"4 2"5 2"4 2" "6 2"5 2" 26
Human serum pool 1"1 1"1 1-9 2" 2" 2"2 26
FT4 Lyphochek I 6"3 6"7 6"4 2"5 2-6 6"6 4-5 26
(pmol/l) Lyphochek II 17"9 20"8 18"8 3-1 2"7 19"8 3"0 26
Lyphochek III 83"2 81"2 73"2 3"2 4"8 72-3 8"5 26
Kit control 12"0 11"7 10"1 3"8 4"7 10"9 7-1 26
Human serum pool 16"6 14"6 2"1 3"5 15-6 5"7 26
T3 Lyphochek I 0"9 0-9 5-4 26
(ng/ml) Lyphochek II 2"0 2"0 3"2 26
Lyphochek III 4"2 3-3 6" 26
Calibrator 3c 1"0 1-1 7-7 26
Human serum pool 1"8 2" 26
Full calibration: CA 15-3, CEA (update), PSA, FT4; Recalibration: AFP, CEA, TSH, T3.
Insufficient serum available.
Values in brackets: assigned values not yet specified for CEA (update).
Different human serum pool on day 2.
Accuracy
The results of the comparison of mean values with
assigned values of control samples are listed in table
3(b). All results were within the acceptable range defined
for COBAS Core EIAs.
The mean values obtained with the CEA (update) assay
for the Lyphochek Immunoassay Control Serum Levels
1, 2, and 3 were 10% below the assigned value. Since the
target value for this new assay still has to be established,
the assigned value for the existing CEA assay was used for
the evaluation of results.
Automatic versus manual dilution
The dilution performed by COBAS Core II was more
precise than the manual dilutions for all dilution ratios
investigated. This is obvious from both the scatter of the
replicate values and the mean values given in figure 2(a)
and 2(b), and table 4. However, a single outlier was
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Table 3(b). Accuracy with control sera: recovery range.
Analyte Control material
Accuracy recovery range
Assigned Mean
value value %min %max
AFP Lyphochek I
(ng/ml) Lyphochek II
Lyphochek III
Kit Control
Ca 15-3 BiorefRM 16 low
(U/ml) BiorefRM 16 high
Kit Control
CEA Lyphochek I
(ng/ml) Lyphochek II
Lyphochek III
Kit Control
CEA Lyphochek I
(update) Lyphochek II
(ng/ml) Lyphochek III
PSA Lyphochek I
(ng/ml) Lyphochek II
Lyphochek III
Kit Control
TSH Lyphochek I
(mIU/1) Lyphochek II
Lyphochek III
Kit Control
FT4 Lyphochek I
(pmol/1) Lyphochek II
Lyphochek III
Kit Control
T3 Lypochek I
(ng/ml) Lyphochek II
Lyphochek III
25-0 25"8 100 107
112"0 120"4 104 110
248"0 254"9 95 104
31"3 31"1 94 103
19-0 20-0 102 111
67"0 67"7 99 107
31"0 32"3 100 111
2"8 2"9 93 107
13"1 14-1 92 116
29"6 29" 90 103
7-5 7"4 92 107
(2"8) 2"5 (84 99)
(13-1) 11.8 (83 93)
(29-6) 25-6 (84 90)
2-6 2"6 95 109
8-6 10.0 112 119
79.8 91.5 97 117
10.9 10.9 97 101
0.97 0.90 85 93
6-4 6.6 101 108
22"5 23"6 100 108
2-4 2.4 99 105
6-3 6"5 100 110
17.9 19-7 107 113
83-2 68.9 77 90
12"0 11.1 83 97
0-9 0.9 93 104
2"0 2"0 99 111
4"2 3-2 73 81
observed on the second day with the automatic dilution
1:100, for which no explanation could be given.
The inter-assay CV for a human serum pool (CEA
concentration 96 ng/ml) and for a Lyphochek Control
Serum (AFP concentration 252 ng/ml) both automati-
cally diluted to 1:10 by the COBAS Core I I system. An
inter-run variation of 7"6% was observed for CEA, a CV
of3"2% was observed for AFP. This is within the range of
CVs found with undiluted samples for the COBAS Core
CEA assay (see table 3[a]).
Method Comparison
Table 5 lists the numerical data obtained in the method
comparison. Diagrams obtained in the method compar-
ison study are shown in figure 3. Method comparisons
for TSH and T4 yielded Spearman coefficients of cor-
relation (rs) of0"97 and 0"917, respectively. The slopes of
the regression equation were close to unity, with the
values for TSH and T4 in the COBAS Core assay
differing from those in the Abbott AxSYM by 8% and
12%, respectively. The data for T3 showed wider spread-
ing around the regression line as did TSH and T4
(rs 0.784).
For nine patient samples, significantly different results
were found for T3 and T4. These differences were
confirmed by a rerun of the same sample on both
analysers, as well as determination of T3 and T4 in up
to four different samples from the same patients. The
reasons for the discrepant T3 and T4 results could be due
to human anti-mouse IgG antibodies (HAMA, hetero-
philic antibodies) being formed in patients who have
received mouse immunoglobulins as part of diagnostic
immunoscintigraphy or immunotherapy. These can react
with reagent antibodies, leading to false-positive results.
These heterophilic anti-IgG antibodies can also occur in
patients who have had fresh-cell therapy. So, samples
with very high values were excluded as some of the
cancer patients had received immunotherapy; the high
T3 and T4 values were probably due to these hetero-
philic antibodies.
In addition, some drugs cause increased protein binding,
leading to increased serum T3 and T4 levels. Therefore,
T3 and T4 tests may be abnormal. Different test methods
may be affected differently by these conditions. Data on
the use ofdrugs for patient treatment were not available.
Some values measured in severely ill patients were
excluded from the correlation study, because it is known
that critical illness can have significant effects on thyroid
function tests.
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Figure 1. Precision results of the daily quality control (bars represent maximum and minimum variation in the daily quality control as
measured in August and October).
Very good agreement was observed when comparing the
COBAS Core AFP assay with the AFP assay on Abbott
AxSYM.
Good coefficients of correlation (all above 0"98) for CA
125 and CA 15-3 were found when comparing the
COBAS Core assays with the routine method on the
Abbott IMx System. One discrepant result was found in
the method comparison CA 125 (COBAS Core II:
3010U/ml, Abbott IMX 1295 U/ml). A possible expla-
nation could be the use of different catcher antibodies
and therefore a slightly different specificity. In addition,
the difference of the results is clinically not relevant.
A slope of 1"28 was found for the COBAS Core CEA
assay. It is reported that certain tumour marker values,
particularly CEA, are highly dependent upon the
method used [16]. The different antibodies used in the
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Figure 2. Diagrams obtained in the method comparison study.
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Table 4. Comparison of automatic versus manual dilution for
PSA in ng]ml.
Automatic dilution Manual dilution
Dilution Pool Specimen Pool Specimen
1:10
1:50
1:100
Median 389 379
Min 387 361
Max 406 390
Range 19 29
Median 396 1895 430 1878
Min 376 1797 391 1756
Max 411 1919 452 2025
Range 35 122 61 270
Median 363 1845 408 1940
Min 352 1673 391 1897
Max 374 1870 431 1971
Range 22 197 40 74
assays may have small differences in their affinity for
CEA, leading to slightly different values between meth-
ods.
PSA results ranging from 0 ng]ml to 1040 ng/ml were
found to be 42% higher in the COBAS Core PSA assay
than in the Abbott PSA assay. However, when interpret-
ing this finding, it is important to consider that the
sample number was rather small (N 44) and was not
evenly distributed over the whole analytical range; and
the COBAS Core PSA EIA is standardized against the
Stanford standard with a PSA:ACT complex to free PSA
ratio of 9:1. This complex/free PSA ratio cannot be
assured in patients in later stages of cancer [17]. PSA
concentrations of above 20ng/ml were observed in 12
patient samples.
For COBAS Core II a fixed time of 35 min was deter-
mined, and the variable time per test was 3"5s. For
comparison, the fixed time determined with the ACS"
180 in a multicentre evaluation [18] was 12"2min, and
the variable time was 12s. In another time study
performed with the Du Pont Dimension 380 [19] analy-
ser, the fixed time was 26 min, and the mean value of the
variable times was 2"5 s.
In order to compare these data with the times deter-
mined on the Abbott AxSYM, some COBAS Core II
data were normalized to the true laboratory environ-
ment: the analyser is always in the standby mode (i.e.
never switched off), equipped with an automatic water
supply unit and connected to a laboratory information
system. Under these circumstances, fixed times of 29 min
were obtained for both analysers, whereas the variable
time per test on COBAS Core II was slightly lower (1" s)
than on Abbott AxSYM (1"9 s).
The short variable time on COBAS Core II is due to the
automatic dilution feature, thus reducing sample prep-
aration time and operator interaction to a minimum and
therefore compensating for the time saving because ofless
post-diluted samples on Abbott AxSYM (higher measur-
ing range ofAbbott CEA and/3-hCG assay).
The COBAS Core II requires about 10min for daily
maintenance and about 30min for the weekly mainte-
nance, whereas the Abbott AxSYM requires about
10min for the daily, and about 40min for the weekly
maintenance.
Taking total processing times into account only, the
Abbott AxSYMTM was faster than COBAS Core II (by
an average of 44 min per day). However, only small
batches of 12-26 samples per day were analysed in this
time study. Therefore the shorter incubation time for
some Abbott assays has more effect on the total proces-
sing time than does the shorter work cycle time of the
COBAS Core II.
Time study
Start-up time, supply of consumables, waste disposal,
preparation time for calibrators, controls and reagents,
and all maintenance and shut-down procedures were
measured for ’fixed’ times. The ’variable’ times included
all procedures dealing with preparation and handling of
the samples.
Routine simulation
The ease of use and flexibility of the COBAS Core II
analyser was assessed by running the system in a routine
environment in parallel with the main routine analyser.
In total, up to 26 samples per day, which is equal to 105
tests per day, were processed. The following assays were
Table 5. Method comparison studies in human sera with COBAS Core H (y) and comparative methods (x). Regression analyses
(y a + bx) were performed according to Passing and Bablok, see text.
Correlation:
Reference Regression equation: coefficient Sample Minimal Maximal
Analyte instrument Passing-Bablok Spearman (rs) size (N) value value
AFP Abbott AxSYM y "01 x 0-08 0"932 30 "33 ng]ml 114 ng]ml
CA 125 Abbott IMx y 1-11 x + 5"23 0"981 24 6"4 U/ml 3620 U/ml
CA 15-3 Abbott IMx y 0"94 x 0"22 0"981 93 5"49 U/ml 8080 U/ml
CEA Abbott AxSYM y-- 1"28 x + 0"11 0"942 174 0"4 ng/ml 530 ng/ml
TSH Abbott AxSYM y 0"92 x + 0-03 0"970 378 0"0 mlU/1 19-6mIU/1
T3 Abbott AxSYM y 1-29 x 0"28 0-784 290 0-34 ng/ml 2"72 ng/ml
T4 Abbott AxSYM y 1" 12 x + 0"69 0"917 295 3"76 gg/dl 20"432 lag/dl
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used on both the COBAS Core II and the Abbott
AxSYM: TSH, T4, T3, AFP, /3-hCG, CA 19-9, CEA,
and PSA. Barcoded samples were used on both analysers
and, in addition, the COBAS Core II was working with
barcoded control sera. The COBAS Core was not
connected to the laboratory information system.
Conclusions
Overall experience with the COBAS Core II was very
positive. It is a well designed immunoassay system with
some strong features:
(1) The software is user friendly, easy to learn and with a
good screen design and presentation.
(2) The automatic pre- and postdilution is very flexible,
exhibiting superior performance compared to
manual dilution.
(3) With the colour coding concept of the software and
the use ofLED indicators for the continuous loading
of the sample and reagents, the operator always has a
good overview of the instrument status.
(4) The use of a factory-stored calibration curve saves
time and reduces costs: for recalibration just one
calibrator is required. In addition, calibration inter-
vals for each test can be entered: when the defined
interval for the calibration has been reached, the test
concerned is highlighted.
Areasfor improvement
Improvements should be made in the following areas:
(a) The measuring range of the CEA and/3-hCG assay
should be extended for samples exceeding the existing
measuring range (patients with malignant tumours).
(b) The quality control software should include a graphi-
cal display and validation criteria.
(c) An emergency stop feature should be added to allow
the operator to interrupt the processing of samples.
Problems occurring during the evaluation
In general, the COBAS Core II was very reliable, with
only some minor instrument-related problems encoun-
tered during the evaluation. It should be noted that the
instrument tested was from the first pilot production. On
one occasion, a needle breakage occurred and the
analyser did not stop automatically (Roche Diagnostics
are correcting this problem).
In summary, COBAS Core II demonstrated good analy-
tical performance and good practicability in routine use,
especially for samples requiring a post-dilution step.
Along with the broad consolidated test menu of 45 tests,
this analyser proved to be extremely efficient.
Some small improvements have now been made to the
instrument to solve the problems which occurred during
the evaluation. As part of a continuous development
programme, updated versions ofCEA and fl--HCG with
an extended measuring range will shortly be launched.
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